To study the possible therapeutic utility of microcin J25 (MccJ25), a peptide RNA polymerase inhibitor.
Introduction
Escherichia coli microcin J25 (MccJ25) is a plasmid-encoded antibiotic peptide consisting of 21 L-amino acid residues, which is primarily active on Gram-negative bacteria related to the producer strain, such as E. coli, Salmonella and Shigella strains. 1, 2 The structure of MccJ25 consists of an amino acid backbone chain (G 1 -G-A-G-H 5 -V-P-E-Y-F 10 -V-G-I-G-T 15 -P-I-S-F-Y 20 -G), containing a lactam linkage between the a-amino group of Gly 1 and the g-carboxyl of Glu 8 , forming an eight-residue ring (Gly 1 -Glu 8 ) denominated the lariat ring. 3 -5 The 'tail' (Tyr 9 -Gly 21 ) passes through the lariat ring, with Phe 19 and Tyr 20 straddling each side of the ring, thus sterically trapping the tail within the ring in a non-covalent way. MccJ25 exhibits strong antimicrobial activity in the range from nanomolar to micromolar when tested in artificial media or buffer systems in vitro. However, the efficacy of MccJ25 in complex fluid matrices such as whole blood, plasma and serum has not yet been assessed. This could be of direct relevance to the potential therapeutic applications of this antibiotic. In this connection, it is well known that antimicrobial peptides from several sources often exhibit strong antimicrobial activities when tested in artificial media or simple buffer systems in vitro; however, in complex fluid matrices such as whole blood, plasma and serum, they tend to show relatively poor activity, since they are rapidly inactivated by peptidases or blocked by proteins. Alternatively, blood and blood fractions may contain components that amplify antimicrobial peptide actions against target pathogens, resulting in enhanced pathogen killing. The present investigation tested the antimicrobial peptide MccJ25 to define potential peptidebiomatrix interactions, using a conventional antibiotic, ampicillin, as a comparator. Another objective was to study the in vivo efficacy of MccJ25 in a murine model of infection with Salmonella Newport. The results demonstrated that MccJ25 exerts a remarkable antimicrobial activity in biomatrices and in in vivo conditions.
Materials and methods

Antimicrobial agents and microorganism
MccJ25 was purified as described previously. 6 Pure MccJ25 and ampicillin (Sigma Chem Co.) were suspended in methanol and water, respectively, prior to use. MccJ25 was diluted with sterile distilled water containing 0.01% Tween 80.
An MccJ25-supersusceptible clinical isolate of Salmonella Newport was used as a target organism in these studies [MIC of MccJ25, 0.02 mM (0.042 mg/L)]. For assays described subsequently, the microorganism was cultured to mid-logarithmic phase in Luria broth (LB) at 378C with agitation, harvested by centrifugation, washed and resuspended in saline (NaCl 0.9%). Inocula were validated by cell viable counts.
Assays with biomatrices
The antimicrobial activity of MccJ25 in human whole blood and homologous plasma and serum fractions was assessed. For a given experiment, 20 mL of fresh whole blood was obtained from a healthy volunteer. Heparin (10 units/mL) was used to anticoagulate a portion of the whole-blood sample. A part of the heparinized whole blood was set aside, and the rest was subjected to low-speed centrifugation (210 g), yielding a plasma supernatant. These preparations comprised the whole-blood and plasma biomatrices, respectively. The remaining non-anticoagulated whole blood was allowed to spontaneously clot for 30 min and centrifuged (300 g) to yield homologous serum (that is, derived from the same donor whose whole blood was also studied). The serum was heated at 568C for 30 min to obtain heat-inactivated serum.
The extent and durability of MccJ25 activity in human whole blood and homologous plasma and serum fractions were assessed. MccJ25 (1 mg/mL) was incubated for 24 h at 378C in whole blood, plasma, serum and inactivated serum. Serial double dilutions of each mixture were then prepared. At time zero and after incubation, 10 mL of each dilution was spotted onto LB plates. After the drops had dried, the plates were overlaid with 4 mL of soft agar inoculated with 10 6 cells of Salmonella Newport. After overnight incubation at 37ºC, the plates were inspected for the size of the inhibition halos. For comparison, the stability of microcin was tested in parallel in a conventional medium (LB).
To compare the antimicrobial efficacy of MccJ25 and ampicillin, the antibiotics were added to 1 mL of each matrix simultaneously with pathogen inoculation (10 mL, yielding a final inoculum of 10 6 cfu/mL). After 2 h of incubation, the mixtures were vortexed to ensure dispersion, and 10-fold dilutions in saline were quantitatively cultured onto LB agar plates. For comparison, the antimicrobial activities of both antibiotics were tested in LB medium.
Haemolysis assay
Blood was drawn with heparin as anticoagulant, processed and assayed immediately. The erythrocytes were spun at 1000 g, washed three times in saline, and about 10 8 cells, suspended in 100 mL of saline, were added to glass tubes containing 900 mL of MccJ25 solution (1000 mg/mL) in saline, saline alone (for baseline values) or distilled water (for 100% haemolysis). After incubation at 378C for 30 min, samples were centrifuged and the haemolytic activity was assessed as a function of haemoglobin release by measuring the absorbance of 500 mL of supernatant (540 nm).
Evaluation of MccJ25 activity in vivo and pharmacokinetic studies
Groups of five mice of 28-32 g were inoculated intraperitoneally with 10 6 cells of Salmonella Newport. MccJ25 or vehicle alone (sterile water or saline), as a control, was administered intraperitoneally 2 h following bacterial challenge. After 1 or 6 days, depending on the experimental scheme (Table 1) , spleen and liver were excised and homogenized. The number of viable organisms was determined by plating dilutions of the homogenates on LB agar.
Studies of MccJ25 pharmacokinetics in plasma after administration of a single dose were performed with mice treated with three different intraperitoneal doses of the antibiotic (7, 18.18 and 36.36 mg/kg). Blood samples were obtained from the tail at different times. Microcin concentration in plasma was determined by the critical dilution method, by comparison with a reference purified sample of the antibiotic titrated in parallel with the unknown samples. The pharmacokinetic parameters determined were half-life (t 1/2 ) and maximum concentration of drug in serum (C max ) by using the TopFit software. Half-life was calculated as the average of the half-lives obtained from the curves for each of the doses tested. Results are expressed as the mean + SD of the log cfu (n ¼ 10).
MccJ25 efficacy in vitro and in vivo
Results
Stability of MccJ25 activity in biomatrices
MccJ25 has been shown previously to be stable upon protease treatment and heating for 30 min at 1208C. 1 In the present work, by using an ex vivo assay, we evaluated the extent and durability of MccJ25 activity in complex fluid biomatrices. To this end, the antibiotic was incubated for 24 h in whole blood, plasma and serum, as well as in LB medium. As shown in Figure 1 , the inhibition zones produced by 1/1024 dilutions of the incubation mixtures had the same size as those obtained at time zero. We conclude that MccJ25 activity is not affected by any component of blood-derived biomatrices. In addition, MccJ25 did not show any haemolytic activity on human erythrocytes.
Antimicrobial activity of MccJ25 in different biomatrices
Incubation of Salmonella Newport in whole blood and plasma did not cause a significant change in cfu/mL values, suggesting that these biomatrices have minimal inherent antibacterial activity (Figure 2 ). On the contrary, a decrease from 10 6 to 10 3 cfu/mL was observed in intact serum. This reduction was not observed in heat-inactivated serum, indicating the presence of an intrinsic activity against Salmonella Newport in intact serum. A similar antibacterial activity in serum has been described for other microorganisms. 7 In LB medium, an inoculum of 10 6 cfu/mL of Salmonella Newport yielded a mean of 10 8 cfu/mL after 2 h of incubation at 378C. When 10 6 cfu/mL of Salmonella Newport was inoculated into LB containing either 0.1 or 1 mM MccJ25, a decrease to 3 log 10 and 2 log 10 cfu/mL, respectively, was observed. Similar results were obtained when the inoculation was done in biomatrices containing the same concentrations of MccJ25. These results indicated that MccJ25 exerts a potent antimicrobial activity in the biomatrices assayed. For comparison, we tested the activity of ampicillin [MIC for Salmonella Newport, 8.41 mM (3.12 mg/L)] under the same conditions. As shown in Figure 2 , as low a concentration of MccJ25 as 0.1 mM has an activity higher than that of 1 and 130 mM ampicillin in both whole blood and plasma. Thus, on a molar basis, MccJ25 is considerably more potent than a conventional antibiotic. (1 mg/mL) was incubated for 24 h at 378C in LB (1), plasma (2), whole blood (3), inactivated serum (4) and serum (5), and the biological activity was assayed by a spot-on-lawn test. For comparison, the halos given by a 1/1024 dilution of each mixture at time zero (T0) and after 24 h of incubation (T24) are shown. 3 mg/mouse, either every 4 h for 1 day or every 24 h for 6 days, decreased significantly (P 0.05) compared with those in control mice (Table 1) .
MccJ25 reduces cfu counts in spleen and liver
Three days after inoculation with 10 6 cells of Salmonella Newport, the animals showed the same signs of disease as those described for Salmonella Typhimurium infection. 8 No mortality was observed under these conditions up to day 7. However, when mice were inoculated with 10 8 cells of Salmonella Newport, 70% of the animals died over the same period.
Discussion
Cationic antimicrobial peptides have in recent years been attracting increasing interest from both the scientific community and the pharmaceutical industry for their potential as new therapeutic agents. For example, the 55 kDa bactericidal/permeabilityincreasing protein (BPI) is a neutrophil-derived polypeptide belonging to a family of lipid and endotoxin-binding proteins. In multiple animal models, a recombinant amino-terminal fragment of BPI, rBPI(21), is non-toxic and protects against Gram-negative bacteria and endotoxin. In humans, rBPI(21) is also non-toxic and non-immunogenic and has undergone Phase II/III clinical trials with apparent therapeutic benefit. 9 However, most of these peptide agents lack specificity and might be too toxic for systemic treatment. 10, 11 Therefore, topical use has been chosen for various antimicrobial peptides that are currently undergoing clinical trials. 12, 13 The Food and Drug Administration recently approved the use of daptomycin, a cyclic lipodepsipeptide antibiotic, for the treatment of complicated skin and skin structure infections caused by several Gram-positive bacteria. 14 The potential interactions between a given antimicrobial peptide and blood components are multifactorial. For example, whole blood and other fluid biomatrices may contain binding or blocking proteins that may inactivate such a peptide. It is well recognized that antibiotics which are highly bound to serum proteins have reduced antibacterial activity when they are tested for in vitro activity in the presence of serum proteins, since only free drug is available for antibacterial activity. 15 On the other hand, in vitro synergy between antibiotics and serum components, including antibody and complement, has been reported 16 -18 and may also be expressed in the responses of patients during antimicrobial chemotherapy. Few MIC studies have attempted to include host factors, although it is known that several variables, including serum proteins, phosphates, osmolarity, divalent cations and pH, can affect the activity of certain antimicrobial agents. 19 Similarly, blood may contain peptidases that degrade the peptide over time.
In this paper, using an ex vivo assay, we evaluated the extent and durability of the peptide antibiotic MccJ25 in complex fluid biomatrices such as human whole blood, plasma and serum compared with those in conventional laboratory media. The antibiotic was shown to be as effective in biomatrices as in artificial media, indicating that its antimicrobial activity was not affected by any blood component. This constitutes an important advantage which distinguishes it from other peptides with therapeutic potential. Besides, the antimicrobial activity in biomatrices appeared to be significantly higher than that of a conventional antibiotic, ampicillin, at least for Salmonella Newport.
Many antimicrobial peptides have the disadvantage of being cytotoxic and/or erythrolytic, and this could limit their potential therapeutic utility. In the present study, we show that MccJ25 has no haemolytic activity, which suggests that it could be harmless for other mammalian cell types.
Another interesting finding of this study is that MccJ25 displays a prolonged systemic antimicrobial activity in a mouse infection model. Intraperitoneal administration of the antibiotic resulted in a significant reduction in the bacterial number in both the spleen and liver of mice infected with Salmonella Newport. Although additional studies are required to improve the therapeutic window and potency of MccJ25, our results suggest that this antibiotic has potential for systemic administration and treatment of otherwise antibiotic-resistant infections.
